SCHEMBL17075508

SCHEMBL17075508

CC(C)OCCNc1ncc(C(=O)O)cn1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 9/20 0.48
CSNK2A1 P68400 2/20 0.46
CSNK2A2 P19784 1/20 0.46
CSNK2B P67870 1/20 0.46
HCAR2 Q8TDS4 1/20 0.43
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GSK3B P49841 1/20 0.39
MAPT P10636 1/20 0.39
ACACB O00763 1/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
VNN1 O95497 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16824292 0.84 HCAR3 (0.66) HCAR3CSNK2A1HDAC3HDAC1HDAC2
SCHEMBL17075527 0.81 HCAR3 (0.48) HCAR3CSNK2A1HCAR2HDAC3HDAC1
SCHEMBL186222 0.78 HCAR3 (0.63) HCAR3CSNK2A1HDAC3HDAC1HDAC2
SCHEMBL17075530 0.78 HCAR3 (0.55) HCAR3CSNK2A1HDAC3HDAC1HDAC2
SCHEMBL18173893 0.77 HCAR3 (0.64) HCAR3HCAR2HDAC3HDAC1HDAC2
SCHEMBL9322209 0.76 KMT2A (0.50) HCAR3CSNK2A1CSNK2A2CSNK2BTSHR
SCHEMBL186359 0.74 HCAR3 (0.61) HCAR3CSNK2A2CSNK2BHCAR2HDAC3
SCHEMBL15423534 0.74 ALDH1A1 (0.58) TSHRL3MBTL1KDM4EMAPTALDH1A1
SCHEMBL34473008 0.73 HCAR3 (0.42) HCAR3HCAR2HDAC3HDAC1HDAC2
SCHEMBL19447774 0.73 AOC3 (0.41) TSHRHDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 US disclosed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 US disclosed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 EP disclosed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 EP disclosed
US-20170247378-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2017-08-31 US disclosed
US-20170247378-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2017-08-31 US disclosed
US-20170247378-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2017-08-31 US disclosed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 US disclosed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 US disclosed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 US disclosed
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2016-02-18 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH HCAR3 1797/4885CSNK2A1 2841/4885CSNK2A2 2430/4885
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH HCAR3 1797/4885CSNK2A1 2841/4885CSNK2A2 2430/4885
US-20170247378-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, SSB, XDH HCAR3 1797/4885CSNK2A1 2841/4885CSNK2A2 2430/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 HCAR3 2704/4885CSNK2A1 1575/4885CSNK2A2 1433/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 HCAR3 2704/4885CSNK2A1 1575/4885CSNK2A2 1433/4885
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, AOC3, IL4I1 HCAR3 722/4885CSNK2A1 2493/4885CSNK2A2 2506/4885
US-20150258101-A1 NEW COMPOUNDS AOX1, QSOX1, MAOB HCAR3 985/4885CSNK2A1 3647/4885CSNK2A2 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.